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Abstract
Introduction Several pharmacological treatments aiming at a better symptomatic control of osteoarthritis (OA) are used in 
daily practice but their efficacy is often disputed. The purpose of this network meta-analysis (NMA) is to assess the efficacy 
on pain and function of the drugs that are most widely prescribed against knee OA.
Methods Medline, Scopus, and Cochrane database of systematic reviews were searched for randomized controlled trials 
published up to August 2019 and assessing the efficacy of knee OA treatments using a 6-month time horizon. Pain and func-
tion changes from baseline were the primary outcomes. A Bayesian network meta-analysis was run and standardized mean 
differences (SMDs) with 95% credibility intervals (95% CrIs) were calculated.
Results 9697 references were identified and 80 RCTs were concordant with our inclusion criteria (79 studies involving 
15,609 individuals reported pain outcomes and 55 studies involving 13,655 individuals reported function outcomes). A 
significant decrease in pain was observed for the intra-articular (IA) combination of hyaluronic acid (HA) and triamcinolone 
(SMD − 0.49, 95% CrI − 0.78; − 0.19), vitamin D (SMD − 0.31, 95% CrI − 0.56; − 0.06), IA HA (SMD − 0.29, 95% CrI 
− 0.40; − 0.17), prescription-grade crystalline glucosamine sulfate (pCGS) (SMD − 0.29, 95% CrI − 0.58; − 0.004), and 
prescription-grade chondroitin sulfate (pCS) (SMD − 0.26, 95% CrI − 0.44; − 0.08). Significant improvements in physical 
function were found with pCGS (SMD − 0.44, 95% CrI − 0.66; − 0.21), vitamin D (SMD − 0.30, 95% CrIs − 0.49; − 0.11) 
and IA HA (SMD − 0.21, 95% CrIs − 0.31; − 0.11).
Conclusion Six months of treatment with IA HA, pCGS, pCS, vitamin D and the combination of IA HA and triamcinolone 
improve pain and/or physical function in patients suffering from knee OA.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 5-020-01423 -8) contains 
supplementary material, which is available to authorized users.
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1 Introduction
Osteoarthritis (OA) is a highly prevalent degenerative age-
related disease characterized by joint pain and function dis-
ability leading to clinically relevant outcomes including loss 
of motion, impairment in quality of life, and a higher risk 
of mortality [1–3]. The incidence of OA is rising due to the 
increase in life expectancy and in the prevalence of obesity, 
and is responsible of an ever-growing societal burden [4, 5]. 
The knee is the most common location of OA and leads to 
the highest clinical and financial burden [6, 7].
The objectives of treating OA are to reduce symptoms 
and presumably to decrease disease progression. Several 
pharmacological treatments aiming at a better symptomatic 
control of OA are currently prescribed, but their efficacy has 
been widely challenged. Discrepancies observed in the treat-
ment guidelines recently issued by various respected scien-
tific societies—for example, the European Society for Clini-
cal and Economic Aspects of Osteoporosis, Osteoarthritis 
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Key Points 
Because the efficacy of pharmacological treatments 
aiming at a better symptomatic control of osteoarthritis 
is often disputed, we performed a systematic review and 
network meta-analysis to assess the efficacy on pain and 
function of the drugs which are most widely prescribed 
against knee osteoarthritis.
Network meta-analysis including 79 randomized con-
trolled trials (15,609 individuals), showed that pain was 
improved following 6 months of treatment with intra-
articular hyaluronic acid, prescription-grade crystalline 
glucosamine sulfate, prescription-grade chondroitin 
sulfate, vitamin D and the combination of IA hyaluronic 
acid and triamcinolone.
Network meta-analysis including 55 randomized con-
trolled trials (13,655 individuals) showed that function 
was improved following 6 months of treatment with 
intra-articular hyaluronic acid, prescription-grade crys-
talline glucosamine sulfate, and vitamin D.
and Musculoskeletal Diseases (ESCEO) [8–10], the Osteo-
arthritis Research Society International (OARSI) [11], the 
American College of Rheumatology (ACR) [12], the Euro-
pean League Against Rheumatism (EULAR) [13]—gener-
ate confusion and uncertainties in the minds of clinicians 
responsible for the daily management of knee OA.
Network-meta-analyses (NMA) are seen as providing a 
high level of scientific evidence. They allow comparison of 
different treatments, making direct and indirect comparisons 
possible within a network of randomized controlled trials. 
Such analyses enable measurement, in a robust and unbiased 
way, of the efficacy of an intervention in a clinical context. 
To date, one single NMA has been published to assess the 
efficacy of the symptomatic treatments used in knee OA 
[14]. Whereas methodologically robust, the conclusions of 
this NMA are difficult to translate into daily practice because 
of its time-horizon set up at 12 months. Even if OA is a pro-
gressive chronic disorder that requires long-term manage-
ment, a very restricted number of treatments are prescribed 
continuously for 12 months or have a carry-over effect main-
tained for up to 1 year.
To assess and compare the efficacy of a practically rel-
evant panel of knee OA treatments, we developed an NMA 
with a time-horizon of 6 months. Such a duration is con-
sistent with the prescribing practices of OA clinicians. It is 
also the duration of treatment recommended by the Euro-
pean Medicines Agency (EMA) for studies of new chemi-
cal entities applying for a Marketing Authorization for the 
symptomatic treatment for OA [15]. We selected pain and 
function as the outcomes of our NMA to be consistent with 
the EMA and with the US Food and Drug Administration 
(FDA), which recommend them as being the two co-primary 
endpoints required for the assessment of symptomatic drugs 
in OA.
2  Methods
The proposed systematic review and network MA was 
conducted and reported in accordance with the Preferred 
Reporting Items for Systematic Review and Meta-analysis 
(PRISMA) using the Extension Statement for Reporting of 
Systematic Reviews Incorporating Network Meta-analyses 
of Health Care Interventions (PRISMA-NMA) [16] [the 
completed PRISMA-NMA is available in Supplementary 
Table  A1, Electronic Supplementary Material (ESM)]. 
A protocol was developed and published in PROSPERO 
(CRD42020163194) prior to the conduct of the network 
meta-analysis.
Our research project can be summarized with the fol-
lowing PICOs format: P (Population): knee osteoarthritis; 
I (Intervention): any pharmacological treatment for knee 
OA administrated during a continuous period of 6 months 
or more (any form of treatment); C (Comparator): active 
control (another active pharmacological treatment), or pla-
cebo; O (Outcome): pain and function; S (Study design): 
randomized controlled trials (RCTs).
2.1  Literature Search
We searched MEDLINE (via Ovid), Scopus, and the 
Cochrane Database of Systematic Reviews (via Ovid) for 
RCTs assessing the efficacy of knee OA treatments pub-
lished from inception of databases up to August 2019. The 
search was limited to English and French studies [17]. A 
combination of terms of Medical Subject Headings (MeSH) 
and keywords was used in search strategy (search strategies 
for each database available in the ESM, Table A2). Addition-
ally, bibliographies of all included studies were manually 
checked for other potentially relevant publications. Moreo-
ver, references retrieved from previous network meta-anal-
yses, meta-analyses, systematic reviews, and review articles 
performed on the same or a similar topic were hand searched 
and included if consistent with our selection criteria. We 
also searched on clinical trial registries (http://www.clini 
caltr ial.gov) for potential unpublished studies and contacted 
experts in the field to obtain their opinions about our search 
strategy and the included papers.
The search results from the electronic sources and hand 
searching were imported in Covidence software for data 
management.
1949Network Meta-Analysis on Pharmacological Treatments for Knee Osteoarthritis
2.2  Study Selection
Five researchers (CB, AG, LL, VL, and DSR) independently 
conducted the selection of references first based on title/
abstract with every single reference screened by two differ-
ent reviewers. Any discrepancy was resolved through discus-
sion and consensus meetings including all five researchers. 
The same process was used for data extraction and risk of 
bias assessment. As a second step, references were screened 
based on their full text. Excluded studies and reasons for 
exclusion were recorded for all studies excluded in the full-
text paper screening stage. Inclusion of studies was based on 
a list of inclusion/exclusion criteria reviewed by all the five 
researchers (Table 1).
2.3  Data Extraction
Data extraction was performed on an Excel sheet tested a 
priori on a sample of six RCTs to check for accuracy and 
consistency of the extraction file. The following data were 
extracted for each individual RCT: (1) General information 
related to the manuscript and population: first author, year of 
publication, country, characteristics of the population (sam-
ple size, groups, age, sex, body mass index, OA grade, and 
OA duration), funding source/conflicts of interest (COIs) 
of authors. (2) Information related to the treatment: type of 
pharmacological treatment, dose, route of administration, 
length of follow-up. (3) Information related to outcomes: 
type of outcome measured (pain, function), outcome meas-
urement instrument/scale, results of the intervention (change 
from baseline to the end of follow-up period (6 months or 
more) or baseline data and end of follow-up results) for each 
outcome. For pain, when different scales were used within 
the same study for the measure of pain, we extracted, prefer-
entially, first the results of the Western Ontario and McMas-
ter Universities Arthritis Index (WOMAC) pain subscale, 
then the Visual Analogical Scale (VAS) (for pain during 
activity, pain during walking, global knee pain, pain at rest, 
pain during night), and then any other scales/subscales for 
measuring pain. For function, we extracted first the result 
of the WOMAC function subscale [18], and then any other 
scale/subscales measuring function. The Lequesne Index 
(LI) [19] was not considered as a scale of function and was 
therefore not included as outcome.
Authors of individual papers were contacted in case of 
any missing information.
2.4  Risk of Bias Assessment
The Cochrane Risk of Bias (RoB) tool was used to assess 
individual RCT quality [20]. Studies were assessed for 
sequence generation, allocation concealment, blinding 
of participants, study personnel and outcome assessors, 
incomplete outcome data and selective outcome reporting. 
With regard to blinding of participants and personnel, we 
considered explicit declarations by the authors that the study 
was conducted in a double-blind fashion to be sufficient for a 
low risk of bias judgment, provided that no contraindications 
were present. For studies with injectable products, where 
blinding of the person administering the product may not 
have been possible due to a difference in viscosity between 
the products, the study was considered to be at low risk of 
bias if the person carrying out the injection was not involved 
in any other aspect of the study and no other contraindi-
cations were present. For the item on incomplete outcome 
reporting, we only accorded a low risk of bias judgment to 
those studies that carried out their analyses on a (modified) 
intent-to-treat sample, either including all randomized sub-
jects or all randomized subjects who took at least one dose 
of study product, or studies without any dropout.
2.5  Data Synthesis
All the analyses were performed using R package “netmeta” 
and extensions.
2.5.1  Relative Treatment Effect
Because studies can use different scales for measuring out-
comes, changes from baseline to 6-month treatment or more 
(measured with WOMAC subscales, VAS scales, or various 
Likert scales) were translated into standardized mean differ-
ence (SMD, Cohen’s d) effect size, defined as the difference 
in change from baseline between two interventions divided 
by the pooled standard difference (SD) of the difference.
For studies reporting different follow-up outcome results, 
the results of the longest follow-up period were extracted. 
Intent-to-treat data were used when available.
2.5.2  Dealing with Missing Outcomes
We extracted original mean differences and SDs, when 
available, in each individual study. When only baseline and 
follow-up values were available and not the mean differences 
and SDs, we estimated the mean differences and SDs from 
these baseline and follow-up values for each group individu-
ally using the formula proposed in the Cochrane Handbook 
for Systematic Reviews.
When standard errors (SEs) only were reported, we con-
verted them to SDs. If neither SDs nor SEs were available, 
we estimated SDs from p-values or 95% CrIs as described in 
the Cochrane Handbook for Systematic Reviews. If none of 
these options were manageable, we contacted the authors of 
individual studies to ask them for the missing information. 
Finally, our last strategies were to impute missing SDs from 
other studies using the same scale to measure the outcomes 
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or to extract and estimate missing data from figures. When 
only median and interquartile ranges were available, we used 
the formula proposed by Hozo et al. [21] to convert them 
into means and SDs.
SMDs were calculated according to the Cochrane Col-
laboration methods.
Table 1  Inclusion and exclusion criteria for study selection
Inclusion criteria Exclusion criteria
Participants
 Age: adults > 18 years
 Sex: both sexes
 Settings: any Settings: pre-post surgical intervention
Ethnicity: any
 Co-morbidities: any
 Condition: knee OA Condition: concomitant knee OA and hip OA with no separate results 
for knee
Intervention
 Treatment: acetaminophen/paracetamol, vitamin E, vitamin D, hyalu-
ronic acid, methylprednisolone, triamcinolone, celecoxib, diclofenac, 
etofenamate, etoricoxib, licofelone, naproxen, chondroitin sulfate, 
diacerein, glucosamine sulfate (see the complete list with complete 
names of treatments in the search strategy)
Any treatment not currently used for the management of OA
 Type of treatments: monotherapy or any recognized combination of 
treatments
Type of treatments: combination of pharmacological treatments with 
another pharmacological treatment not in the list of inclusion or 
with non-pharmacological treatments (e.g. physical activity, manual 
therapy, physiotherapy, etc.)
Route of administration: any
Length of treatment: 6 consecutive months or + (for IA injections, at 
least 6 months of follow-up)
Comparator
Placebo
Active control (other OA treatment)
Rescue medication
Accepted
Allowed to continue an active treatment of OA if dose is stable through-
out the study OR
Outcome (at least one measure of)
Pain (WOMAC, VAS, SF-36, etc.)
Function (WOMAC, SF-36, etc.)
Study design
RCTs (blind or not blind) Quasi-randomized trials
Cross-over trials (if randomized) for the first part of the study (if at least 
6 months of treatment in this first phase)
Case report
Open-label trials (if randomized) Case series
Post hoc analyses
Congress abstracts of RCTs Protocols of RCTs
Phase II or III clinical trials (not published)
Other
English and French
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2.5.3  Network Meta‑Analyses
Prior to running network meta-analyses (NMA), we assessed 
the transitivity assumption, which implies that studies com-
paring different sets of intervention are sufficiently similar 
to provide valid indirect inferences.
Then, we ran a Bayesian network meta-analysis to syn-
thetize evidence for each outcome. We assumed a single 
heterogeneity parameter for each network. The available 
evidence is presented in a network diagram in which the 
breadth of each edge is proportional to the inverse of the 
variance of the summary effect of each direct treatment 
comparison.
We then estimated the probability for each intervention 
to be ranked as the most effective for a particular outcome 
improvement, given the relative effect sizes as estimated in 
NMA. As described in Salanti et al. [22], we obtained a hier-
archy of the competing interventions using the surface under 
the cumulative ranking curve (SUCRA) and mean ranks. 
SUCRA values are expressed as a percentage, showing the 
relative probability of an intervention to be among the best 
options. The higher value represents the higher probability 
of being the best option.
We also performed a statistical evaluation of consist-
ency, which consists of the agreement between direct and 
indirect evidence. We employed both local and global 
methods to evaluate consistency. Local methods identify 
pairwise comparisons or loops of evidence that might be 
important sources of inconsistency. We also evaluated 
consistency globally, in the entire network, by calculat-
ing the design-by-treatment interaction (X2 test and I2 for 
inconsistency). In case of inconsistency, we tried to find 
an explanation by analyzing the studies and performing 
sensitivity analyses.
2.5.4  Sensitivity Analyses (Exploring Heterogeneity)
We ran a sensitivity analysis by removing studies for which a 
high risk of bias had been found in any of the RoB domains.
2.5.5  Publication Bias
We ran a comparison-adjusted funnel plot for pain and 
function outcome comparing all treatments against placebo 
to detect the presence of any dominant publication bias in 
NMA. Order of treatment was generated according to the 
number of patients included for each treatment.
3  Results
3.1  Literature Search
After removing duplicates between the different databases, 
9,697 studies were screened for titles and abstracts. Among 
these references, 348 were assessed for eligibility by review-
ing full texts. Finally, 80 individual RCTs were included in 
this network meta-analysis (Fig. 1). References of included 
studies are available in the ESM. Reasons for exclusion of 
all papers excluded during the full-text eligibility stage are 
recorded in ESM Table A3.
3.2  Characteristics of Included Studies
Characteristics of the 80 individual studies included in the 
NMA are available in ESM Table A4. Studies were pub-
lished from 1988 to 2019 and included between 40 and 1583 
participants with a total of 15,713 individuals. All but one 
included patients from both genders. More than half of the 
studies were performed on participants 60 years and older 
and the mean duration of treatment was 50 months. Most 
studies included a two-arm study design, but 14 studies 
included a three-arm design, four studies included a four-
arm design, and one other study included a five-arm design. 
Table 2 summarizes the different treatments included in this 
NMA with distribution across pain and function outcomes. 
Risk of bias assessment and summary are available in ESM 
Fig. A1 and ESM Fig. A2.
3.3  Efficacy of Knee Osteoarthritis (OA) Treatments 
on Pain
Pain was investigated in 79 studies (15,609 individuals) 
using 26 different treatments that led to 101 pairwise com-
parisons. The network diagram including those 79 studies 
is shown in Fig. 2.
A significant association with decreased pain was found 
for the combination of intra-articular (IA) HA and triam-
cinolone (SMD − 0.49, 95% CrI − 0.78; − 0.19), vitamin 
D (SMD − 0.31, 95% CrI − 0.56; − 0.06), IA HA (SMD 
− 0.29, 95% CrI − 0.40; − 0.17), pCGS (SMD − 0.29, 95% 
CrI − 0.58; − 0.004), and pCS (SMD − 0.26, 95% CrI − 0.44; 
− 0.08). For pain, the combination IA HA + triamcinolone 
had the highest probability of being the most effective treat-
ment to reduce pain (SUCRA value of 0.88) (see network 
forest plot in Fig. 3). A league table that presents results of 
the network meta-analyses and pairwise meta-analyses is 
available in ESM Fig. A3.
Heterogeneity was significant (p < 0.001, I2 69%) in the 
model but inconsistency statistics revealed no inconsist-
ency between direct and indirect evidence (between-design 
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inconsistency p = 0.094). The comparison-adjusted funnel 
plot for pain efficacy of treatments against placebo suggested 
no funnel plot asymmetry (ESM Fig. A5).
In a sensitivity analysis, we included only studies with no 
risk of bias in any of the Cochrane RoB tool domains (i.e., 
we excluded studies with a high risk of bias in any domain), 
resulting in 30 studies being included (8754 individuals), 17 
treatments and 43 pairwise comparisons. Results still dem-
onstrated an effective effect on pain for pCGS, for the combi-
nation of IA HA + triamcinolone, for pCS for IA HA but also 
for IA methylprednisolone. With a SUCRA value of 0.79, IA 
methylprednisolone was shown as having the highest prob-
ability of being the most effective treatment to reduce pain in 
knee OA in these sensitivity analyses. Within-design hetero-
geneity was still significant (p < 0.001) and between-design 
inconsistency was also significant (p = 0.023). A network 
forest plot of the sensitivity analyses is available in ESM 
Fig. A7.
3.4  Efficacy of Knee OA Treatments on Function
Function was investigated in 55 studies (13,655 individuals) 
using 21 different treatments that led to 84 pairwise com-
parisons. The following treatments were shown to increase 
function: pCGS (SMD − 0.44, 95% CrI − 0.66; − 0.21), 
vitamin D (SMD − 0.30, 95% CrI − 0.49; − 0.11) and IA 
HA (SMD − 0.21, 95% CrI − 0.31; − 0.11). pCGS had the 
highest probability to most improve function (SUCRA value 
of 0.91) (Fig. 4). A league table that presents results of the 
network meta-analyses and pairwise meta-analyses is avail-
able in ESM Fig. A4. On the contrary, piroxicam was shown 
to reduce function (SMD 0.83, 95% CrI 0.02; 1.64).
Within-design heterogeneity was significant (p < 0.001, I2 
52.1%) as well as between-design inconsistency (p = 0.024). 
The comparison-adjusted funnel plot for function efficacy 
of treatments against placebo suggested that there might be 
small-study effects in the NMA (ESM Fig. A6).
Fig. 1  PRISMA flowchart of 
study selection
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Table 2  Number of studies that reported pain or function outcomes that were identified for each treatment
IA intra-articular
Treatment Pain Function
Number of studies Number of individuals Number of studies Number of 
individuals
Placebo 50 4570 38 4056
IA hyaluronic acid 39 3049 25 2233
IA triamcinolone 9 534 7 494
Prescription chondroitin sulfate 10 1200 5 755
IA methypredinosolone 7 586 2 245
Celecoxib 6 1219 6 1214
Glucosamine sulfate 5 548 5 726
Glucosamine + chondroitin sulfate 5 787 5 914
IA hyaluronic acid + triamcinolone 4 251 4 265
Naproxen 4 636 2 446
Vitamin D 4 498 4 571
Prescription crystalline glucosamine sulfate 3 313 3 313
Diclofenac 3 91 2 75
Vitamin E 3 138 2 105
Acetaminophen/paracetamol 2 181 1 108
Avocado soybean unsaponifiables 2 236 2 236
Chondroitin sulfate 2 370 4 631
Piroxicam 1 51 1 52
IA condrotine 1 36 1 36
IA prednisolone 1 40 0 0
IA cortivazol 1 25 0 0
IA dexamethasone 1 25 0 0
IA etofenamate 1 29 0 0
Etoricoxib 1 33 1 33
IA ketorolac 1 16 0 0
Licofelone 1 147 1 147
Fig. 2  Network plot of pain (a) and function (b) efficacy of knee oste-
oarthritis (OA) treatments (breadth of each edge is proportional to the 
inverse of the variance of the summary effect of each direct treatment 
comparison). ACETA acetaminophen/paracetamol, ASU avocado soy-
bean unsaponifiables, CELE celecoxib, CONDRO condrotide, CORTI 
cortivazol, CS chondroitin sulfate, DEXA dexamethasone, DICLO 
diclofenac, ETOF etofenamate, ETORI etoricoxib, GS glucosamine 
sulfate, G+C combination of glucosamine sulfate + chondroitin sul-
fate, HA hyaluronic acid, KETO ketorolac, LICO licofelone, METHYL 
methylprednisolone, NAPRO naproxen, PBO placebo, pCGS pre-
scription-grade crystalline glucosamine sulfate, pCS prescription 
grade chondroitin sulfate, PRED prednisolone, PIRO piroxicam, 
TRIAM triamcinolone, VITD vitamin D, VITE vitamin E
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The sensitivity analysis, including only studies with 
no risk of bias in any of the Cochrane RoB tool domains, 
resulted in the inclusion of 22 studies (7566 individuals), 16 
treatments and 33 pairwise comparisons. Results demon-
strated a significant effect of pCGS (SUCRA value of 0.94, 
as having the highest probability of being the best treatment 
for increasing function) and vitamin D as effective on func-
tion in knee OA patients. Within-design heterogeneity was 
still significant (p < 0.001) but between-design inconsist-
ency was not significant anymore (p = 0.2345). A network 
forest plot of the sensitivity analyses is available in ESM 
Fig. A8.
3.5  Additional Analyses
Effects of treatment on stiffness and joint space narrow-
ing (JSN) have also been explored as additional analyses. 
Forest plots are presented in the ESM files (Fig. A9 and 
Fig. A10). A network meta-analysis on stiffness (38 RCTs, 
10,049 individuals, 19 treatments, 49 pairwise compari-
sons) indicated that only chondroitin sulfate is effective 
against stiffness in knee osteoarthritis (SMD − 0.4 (95% 
CI − 0.74; − 0.05). A network meta-analysis on JSN (14 
RCTs, 3750 individuals, 12 treatment, 28 pairwise com-
parisons) concluded that both pCGS and pCS are effective 
to reduce JSN in knee osteoarthritis with a mean difference 
of JSN of 0.27 (95% CI 0.09; 0.46) mm for pCGS versus 
placebo and 0.13 (95% CI 0.01; 0.25) mm for pCS versus 
placebo, respectively.
4  Discussion
This network meta-analysis, based on 80 RCTs, assessed 
the efficacy of different chemical entities currently used for 
the symptomatic treatment of knee OA. Our results indi-
cate that, when administered for 6 months or more, IA HA, 
pCGS, pCS, vitamin D, and the combination of IA HA + tri-
amcinolone significantly improved pain and/or physical 
function in patients suffering from knee OA. Injections of 
HA + triamcinolone for pain, and pCGS for function, have 
respectively the highest probability of being the most effec-
tive treatment.
Fig. 3  Network meta-analysis forest plot summarizing the efficacity of knee osteoarthritis treatments in reducing pain
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So far, only one NMA [14] previously investigated the 
effects of pharmacological treatments on pain and function 
in patients with knee OA. In this elegant publication, the 
authors selected a time-horizon of 12 months instead of 
the 6 months that we preferred for our present study. They 
included 31 RCTs for pain and 13 for physical function, 
and found significant improvement in pain and function with 
pCGS only. The main variable explaining why we identified 
more treatments potentially affecting knee OA symptoms is 
the time horizon. Indeed, we included studies of a 6-month 
duration rather than concentrating only on duration of treat-
ments of 12 months or more. We subsequently were able to 
include a larger number of RCTs. In fact, several treatments, 
such as non-steroidal anti-inflammatory drugs (NSAIDs) 
or analgesics, are generally prescribed for a shorter dura-
tion than 12 months, because of safety concerns [8, 9, 23]. 
Therefore, clinical trials assessing the efficacy of these med-
ications were often limited to shorter periods rather than 
exposing patients for a 12-month continuous administration. 
Moreover, some IA treatments, such as HA, are commonly 
administered in sequences including one to five injections, 
with intervals between doses usually not exceeding 3 weeks. 
Albeit these treatments are known to generate a prolonged 
benefit, the persistence of their symptomatic effect is sel-
dom still persistent 12 months after the first injection, which 
explains why studies assessing these medications are often 
limited to 6 months [8].
Oral NSAIDS are widely prescribed in OA and their use 
is recommended by most recently published clinical guide-
lines [8, 11–13]. However, we were unable to demonstrate 
a statistically significant benefit of any NSAID on pain or 
function, after 6 months, in knee OA patients. It is notewor-
thy that both celecoxib and naproxen showed trends towards 
a beneficial effect on OA symptoms but the numerical 
improvement observed with these two NSAIDs did not reach 
the level of statistical significance in our study. Once again, 
this may reflect the fact that oral NSAIDs are mainly recom-
mended for intermittent use or short-term courses, rather 
than prolonged continuous treatments [8, 11]. A recent sys-
tematic review and meta-analysis (MA) concluded that the 
NSAID-induced symptomatic benefit observed in knee OA 
peaks after 2 weeks while the drug-related cardiovascular 
and gastrointestinal adverse events reach statistical signifi-
cance as early as 4 weeks [24]. The optimal time-horizon 
of a MA or NMA aiming at a specific assessment of the 
symptomatic effect of NSAIDs in OA should probably be 
much shorter than 6 months. Surprisingly, we also observed 
a negative effect of piroxicam on function as compared to 
placebo. Looking closer to the results, only one study, by 
La Montagna et al. [25], investigated effects of piroxicam 
on function, and the comparator used in this study was 
Fig. 4  Network meta-analysis forest plot summarizing the efficacity of knee osteoarthritis treatments in improving function
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diclofenac. The results provided by the network analysis 
should therefore be interpreted with caution given that only 
one study is included and the observed effect against placebo 
is the result of indirect analyses.
Symptomatic slow-acting drugs for OA (SYSADOAs) are 
recommended by some but not by all guidelines as a useful 
addition to the armamentarium against OA [8, 11–13]. It has 
been suggested that discrepancies between the therapeutic 
value given to glucosamine or chondroitin products in the 
various guidelines may be related to the fact that some of 
the guidance documents distinguish pharmaceutical-grade or 
prescription-only preparations from generics, nutraceutical-
grade or over-the-counter (OTC) formulations, while other 
guidelines consider these products as a whole class with no 
attempt to separate them by grade or brand [26, 27]. Since 
a Cochrane Review and two more recent MAs, conducted 
independently from any corporate funding, concluded 
that all GS or CS products do not share the same level of 
symptomatic efficacy in OA [28–30], our NMA considered 
separately the prescription-grade chondroitin sulfate (pCS) 
and the prescription-grade crystalline glucosamine sulfate 
(pCGS) from the other chondroitin or glucosamine products 
tested in OA studies. Our results support the view that pCS 
and pCGS are more effective in reducing pain in knee OA 
than other glucosamine or chondroitin preparations, which 
do not provide any significant clinical benefit, as outlined in 
previous publications [8, 11, 12]. This difference between 
the various glucosamine and chondroitin preparations was 
confirmed in our sensitivity analysis excluding studies with 
a high risk of bias.
The effect of pCS on function was only borderline sig-
nificant (SMD − 0.16; 95% CI − 0.3; 0.04). Several studies 
of pCS in knee OA selected the Lequesne index (LI) as the 
assessment tool for function. Although a validated instru-
ment for measuring the algo-functional impact of OA, LI is a 
composite index that does not allow discriminating between 
the respective components of pain and function, as the dif-
ferent subscales of the WOMAC do [18, 19]. Since we felt 
it important to separately identify the effects of the different 
drugs on pain and function, we discarded from the analysis 
trials that did not provide separate results of the investiga-
tional product on these two symptoms of OA. We cannot 
exclude that if a specific tool assessing function apart from 
pain would have been selected in the pCS trials, this might 
have positively influenced the outcomes of our assessment 
of the effect of pCS on function.
Acetaminophen/paracetamol is not associated with a 
significant clinical benefit in knee OA. Our results support 
previous reports suggesting that the magnitude of the effect 
of this compound in OA is at best trivial and not clinically 
relevant in patients with knee or hip OA [31, 32]. This 
observation, combined with increasing evidence that aceta-
minophen/paracetamol is linked to a considerable level of 
toxicity, particularly at the upper end of standard analgesic 
doses [33, 34], translated into a negative recommendation 
for the prolonged use of this medication in knee OA in all 
the recently published guidelines [8, 11, 12].
A large number of RCTs investigated the effects of IA 
injections of HA and/or glucocorticosteroids (GCST) on 
pain and function in knee OA. The combination of IA HA 
and triamcinolone, a well-known GCST, was ranked as the 
most effective approach to reduce pain in the general NMA 
and in the sensitivity analysis. Injection of HA alone was 
also beneficial at a 6-month horizon, both on pain and on 
function, while IA administration of GCST alone did not 
provide a similar benefit. This is perfectly in accordance 
with the established pharmacodynamic properties of the two 
products: IA GCST produces a fast but transient benefit, 
which can hardly be expected to last up to 6 months, whereas 
IA HA needs some more latency to show its maximal effect, 
which is expected to be long-lasting for several weeks or 
months [8, 35–37].
Vitamin D reduced pain and improved function in knee 
OA patients. While deficiency in endogenous vitamin D, 
reflected by low levels of circulating 25 OH vitamin D, was 
associated with the onset and progression of knee OA [38], 
maybe through an increased frequency of medial meniscus 
lesions [39], results of individual RCTs were inconclusive 
[40–43]. Their outcomes varied from a non-significant trend 
for symptom reduction [40–42] to a small but statistically 
significant benefit on pain and function after 12 months of 
administration [43].
Our decision to limit this NMA to treatments that are cur-
rently prescribed or recommended in daily practice explains 
why we did not assess treatments that are currently under 
investigation (e.g., tanezumab, fanizumab, lorecicivint, 
etc.) or which, despite their availability for other indica-
tions, are not or no longer commonly prescribed against 
OA (e.g., strontium ranelate, bisphosphonates, calcitonin, 
doxycycline, etc.). We did not include non-pharmacological 
interventions in this NMA neither, albeit all evidence-based 
guidelines agree that the medical management of OA should 
include both non-pharmacological and pharmacological 
treatment modalities [44]. The main differences observed 
between the recently published recommendations [8, 11, 12] 
and the subsequent confusion that these discrepant opin-
ions introduce in the mind of the prescribers are linked to 
the respective value given to the different available medica-
tions. We thus tried to concentrate our efforts on a fair and 
unbiased assessment of the respective symptomatic benefit 
that can be expected from these medications after a 6-month 
treatment.
We considered stiffness as an ancillary outcome of our 
MNA. Indeed, stiffness is not recommended as an appropri-
ate endpoint in the EMA or FDA guidelines for the assess-
ment of new chemical entities aiming at the symptomatic 
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management of knee OA. We also observed a large hetero-
geneity across studies in the tools that were used to report 
this outcome, making its assessment poorly reliable. Our 
results reporting a reduction in JSN with pCGS and with 
pCS are in perfect accordance with previous publications 
showing that pCGS [45, 46] or pCS [47] are able to sig-
nificantly prevent structural progression of osteoarthritis. 
However, in the context of the present investigation, these 
analyses should be interpreted with caution because the 
time-horizon selected for our NMA was 6 months. Mag-
netic resonance imaging (MRI) may provide rapid infor-
mation on the progression of knee OA, hence presumably 
allowing assessment of the structure-modifying properties 
of a drug after a couple of months only [48]. However, 
until now, JSN measured on plain X-rays has been most 
often used as the primary outcome of studies investigating 
a possible effect of a medication on OA structural progres-
sion [49]. All studies that assessed the impact of a drug 
on JSN had a much longer duration than 6 months, often 
up to 2 years [45, 50]. Therefore, assessing the structure-
modifying properties of the treatments included in this 
MNA within such a short timeframe (6 months) could be 
seen as disputable.
Finally, we also discovered a potential small study effect 
in the funnel plot on function. Several potential explana-
tions may be publication bias, selective reporting outcomes, 
or even clinical heterogeneity between patients included in 
large versus in small studies. Most of these factors are nev-
ertheless out of our control. To restrict a maximum publica-
tion bias issue, we performed comprehensive and systematic 
research of the literature. The only limitations of our search 
strategy were that we decided to restrict our search to French 
and English studies, which may have introduced publication 
bias but also that our search was limited to August 2019. 
This last point is a classical issue in conducting and publish-
ing meta-analyses, which is a lengthy process. However, we 
truly believed that, due to our inclusion criteria, we would 
have missed a very restricted number of new studies, with 
a very low probability of significantly altering the current 
results.
5  Conclusion
In this systematic review and network meta-analysis that 
included 80 RCTs, we highlighted that 6 months of treat-
ment of knee OA patients with intra-articular hyaluronic 
acid, prescription-grade crystalline glucosamine sulfate, 
prescription-grade chondroitin sulfate, vitamin D, and the 
combination of intra-articular hyaluronic acid and triam-
cinolone are effective to improve pain and/or function.
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